Hemi Pharma SEMAGLUTIDE 5mg

Product Overview

hemi pharma Semaglutide 5mg is a synthetic GLP-1 receptor agonist designed to mimic the natural incretin hormone GLP-1. It works by acting on appetite regulation and glucose metabolism pathways.

According to FDA-reviewed pharmacological data, semaglutide is used in prescription medications such as Ozempic, Wegovy, and Rybelsus, manufactured by Novo Nordisk, for the treatment of type 2 diabetes and chronic weight management.

The 5mg format is commonly seen in vial-based formulations where the medication is later diluted (reconstituted) into a measurable injectable solution.

Key Features

• 5mg total semaglutide per vial (lyophilized powder format)
• GLP-1 receptor agonist mechanism of action
• Typically administered as a once-weekly subcutaneous injection in clinical use
• Designed for dose titration under medical supervision
• Used in protocols for blood sugar control and weight management (approved indications depend on branded formulation)

Mechanism of Action

Semaglutide works by mimicking GLP-1, a hormone involved in:

• Stimulating insulin secretion when blood glucose is elevated
• Reducing glucagon release from the pancreas
• Slowing gastric emptying
• Increasing satiety and reducing appetite

These combined effects lead to improved glycemic control and reduced caloric intake.

Dosage Context (Important)

Clinical dosing is not based on “5mg vials” directly, but on weekly titrated doses.

According to FDA prescribing guidance:

• Starting dose is typically 0.25mg once weekly
• Gradual increases may occur every 4 weeks depending on response
• Maintenance doses commonly range up to 2.4mg weekly (Wegovy protocol)

⚠️ The 5mg vial requires reconstitution, and final dosing depends entirely on concentration after preparation. Incorrect calculation or measuring errors can result in significant overdosing risk.

Common Clinical Uses (Prescription Only)

• Type 2 diabetes management
• Chronic weight management (obesity treatment)
• Cardiovascular risk reduction in selected patients
  (Indications vary by branded formulation and regulatory approval)

Safety Information

• Prescription-only medication in regulated markets
• Requires gradual dose escalation to reduce gastrointestinal side effects
• Common side effects may include:
  • Nausea
  • Vomiting
  • Diarrhea or constipation
  • Appetite suppression
• Higher-risk concerns include dehydration, gallbladder issues, and rare pancreatitis cases (documented in clinical labeling for GLP-1 drugs)

FDA safety communications also highlight dosing errors as a major risk factor in compounded vial formats due to manual measurement requirements.

Storage

• Unreconstituted: refrigerated or stored per manufacturer instructions
• After reconstitution: typically refrigerated and used within a limited stability window (varies by formulation)

Important Note on Product Variability

“Semaglutide 5mg” may refer to compounded or non-standard vial presentations where concentration, excipients, and stability vary between suppliers. These are not equivalent to FDA-approved prefilled pen systems (Ozempic/Wegovy), which have fixed dosing and built-in safety controls.

I cannot confirm regulatory status or manufacturer authenticity for any non-branded vial labeled “5mg semaglutide” without specific verified sourcing.

looking for more peptides, check our homepage